Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford and its partner organisations have been awarded funding that will support the training of over 175 bioscience graduate students as part of £170 million investment in bioscience by the BBSRC (Biotechnology and Biosciences Research Council, part of UK Research and Innovation).

Oxford-led doctoral training partnership to offer over 175 graduate scholarships in the biosciences © Shutterstock

The total investment will fund 1,700 PhD researchers over five annual cohorts at academic institutions all over the UK under the third phase of UKRI-BBSRC’s Doctoral Training Partnerships (DTP). The Oxford Interdisciplinary Bioscience DTP’s share will be over £14M, and matched funding by partner organisations and industry will bring the total investment in the Oxford partnership to over £20 million

This represents the third phase of BBSRC funding for Oxford’s Interdisciplinary Bioscience DTP programme, an innovative four-year DPhil/PhD programme that aims to equip a new generation of researchers with the skills, insight and knowledge needed to tackle the most important challenges in bioscience research, and develop the world-class, highly skilled workforce the UK needs for its future. Oxford’s Interdisciplinary Bioscience DTP was initially funded in 2012 and is part of the University of Oxford’s innovative, interdisciplinary Doctoral Training Centre.

The Oxford Interdisciplinary Bioscience DTP is led by the University of Oxford, in partnership with eight world-class research organisations. Six of these collaborations, The Pirbright Institute, Oxford Brookes University, Diamond Light Source, ISIS Neutron and Muon Source, STFC Central Laser Facility and the Research Complex at Harwell, continue the successful partnership established in the second phase of DTP funding. For the third phase two new organisations have joined the partnership, the Novo Nordisk Research Centre Oxford (NNRCO), an innovative target discovery and translational research institute which opened in Oxford in 2017; and the Rosalind Franklin Institute, a new national institute based at Harwell dedicated to transforming life science through interdisciplinary research and technology development.

Read more (University of Oxford website)

Similar stories

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

AIMday in Women's Health - registration for academics now open

Events Innovation

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Women's Health.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.

New national study of long-term impacts of debilitating lung damage from COVID-19

Coronavirus COVID-19 General Research

A new national study will investigate the long-term effects of lung inflammation and scarring from COVID-19. The study, launched with £2 million of funding from UK Research and Innovation (UKRI), aims to develop treatment strategies and prevent disability.

Opportunities for final goodbyes must be prioritised in COVID-19 pandemic

Coronavirus COVID-19 General Research

Bereaved relatives described the ongoing pain of being absent at the end of a loved-one's life. Many had not seen their relative for weeks or months due to the pandemic. Opportunities must be prioritised for essential connections between families at end-of-life care.